Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43079 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Lisa Abernathy-Close und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: Mupirocin, Anti-Bacterial Agents, Lupus Erythematosus, Cutaneous, Interferon Type I. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Objective
Cutaneous lupus erythematosus (CLE) is an inflammatory skin manifestation of systemic lupus erythematosus. Type I interferons (IFNs) promote inflammatory responses and are elevated in CLE lesions. We recently reported that CLE lesions are frequently colonized with Staphylococcus aureus . Here, we follow up via a proof‐of‐concept study to investigate whether type I IFN and inflammatory gene signatures in CLE lesions can be modulated with mupirocin, a topical antibiotic treatment against S aureus –mediated skin infections.
Methods
Participants with active CLE lesions (n = 12) were recruited and randomized into a week of topical treatment with either 2% mupirocin or petroleum jelly vehicle. Paired samples were collected before and after seven days of treatment to assess microbial lesional skin responses. Microbial samples from nares and lesional skin were used to determine baseline and posttreatment Staphylococcus abundance and microbial community profiles by 16S ribosomal RNA gene sequencing. Inflammatory responses were evaluated by bulk RNA sequencing of lesional skin biopsies.
Results
We identified 173 differentially expressed genes in CLE lesions after topical mupirocin treatment. Decreased lesional Staphylococcus burden correlated with decreased IFN pathway signaling and inflammatory gene expression and barrier dysfunction. Interestingly, mupirocin treatment lowered skin monocyte levels, and this mupirocin‐associated depletion of monocytes correlated with decreased inflammatory gene expression.
Conclusion
Mupirocin treatment decreased lesional Staphylococcus , and this correlated with decreased IFN signaling and inflammatory gene expression. This study suggests a topical antibiotic could be employed to decrease lupus skin inflammation and type I IFN responses by reducing Staphylococcus colonization. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Michigan, Ann Arbor.
ORCID-Profile: J Michelle Kahlenberg
Förderung
- NIAMS NIH HHS
- NIH HHS
- NIGMS NIH HHS
- Doris Duke Charitable Foundation
- NIAID NIH HHS
- NCATS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institutes of Health
Zitieren
APA
Abernathy-Close, L., Mears, J., Billi, A. C., Sirobhushanam, S., Berthier, C., Lu, A., Zhang, Z., Hurst, A., Gudjonsson, J. E., & Kahlenberg, J. M. (2025). Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species. Arthritis & Rheumatology. https://doi.org/10.1002/art.43079
Vancouver
Abernathy-Close L, Mears J, Billi AC, Sirobhushanam S, Berthier C, Lu A, et al. Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species. Arthritis & Rheumatology. 2025. doi:10.1002/art.43079
BibTeX
@article{AbernathyClose2025,
author = {Abernathy-Close, Lisa and Mears, Joseph and Billi, Allison C and Sirobhushanam, Sirisha and Berthier, Celine and Lu, Annie and Zhang, Zeran and Hurst, Amy and Gudjonsson, Johann E and Kahlenberg, J Michelle},
title = {Topical Mupirocin Treatment Reduces Interferon and Myeloid Signatures in Cutaneous Lupus Erythematous Lesions Through Targeting of Staphylococcus Species},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43079}
}
EUVIMED